KRAS signaling in malignant pleural mesothelioma - Archive ouverte HAL Access content directly
Journal Articles EMBO Molecular Medicine Year : 2021

KRAS signaling in malignant pleural mesothelioma

(1, 2) , (2) , (1, 3) , (1, 2, 3) , (2) , (4) , (5) , (2) , (1, 2, 3) , (1, 3) , (1, 3) , (1, 3) , (1, 3) , (1, 3) , (3, 1, 6) , (3, 1, 6) , (3, 1, 6) , (3, 1) , (1, 3, 7) , (2) , (2, 8) , (9) , (4) , (4) , (5) , (5) , (5) , (5) , (5) , (5) , (5) , (5) , (2) , (2) , (2) , (2) , (1) , (1, 3)
1
2
3
4
5
6
7
8
9
Giannoula Ntaliarda
Hasan Bayram
Didier Jean
Özgecan Kayalar
Deniz Mortazavi
  • Function : Author
Şükrü Dilege
  • Function : Author
Serhan Tanju
Suat Erus
Ömer Yavuz
Pinar Bulutay
  • Function : Author
Pinar Firat
  • Function : Author
Magda Spella
Ioannis Lilis

Abstract

Malignant pleural mesothelioma (MPM) arises from mesothelial cells lining the pleural cavity of asbestos-exposed individuals and rapidly leads to death. MPM harbors loss-of-function mutations in BAP1, NF2, CDKN2A, and TP53, but isolated deletion of these genes alone in mice does not cause MPM and mouse models of the disease are sparse. Here, we show that a proportion of human MPM harbor point mutations, copy number alterations, and overexpression of KRAS with or without TP53 changes. These are likely pathogenic, since ectopic expression of mutant KRAS G12D in the pleural mesothelium of conditional mice causes epithelioid MPM and cooperates with TP53 deletion to drive a more aggressive disease form with biphasic features and pleural effusions. Murine MPM cell lines derived from these tumors carry the initiating KRAS G12D lesions, secondary Bap1 alterations, and human MPM-like gene expression profiles. Moreover, they are transplantable and actionable by KRAS inhibition. Our results indicate that KRAS alterations alone or in accomplice with TP53 alterations likely play an important and underestimated role in a proportion of patients with MPM, which warrants further exploration.
Fichier principal
Vignette du fichier
2021_Blanquart_EMBOMolMed.pdf (19.56 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03483560 , version 1 (16-12-2021)

Identifiers

Cite

Antonia Marazioti, Anthi C Krontira, Sabine J Behrend, Georgia A Giotopoulou, Giannoula Ntaliarda, et al.. KRAS signaling in malignant pleural mesothelioma. EMBO Molecular Medicine, 2021, pp.e13631. ⟨10.15252/emmm.202013631⟩. ⟨inserm-03483560⟩
48 View
108 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More